专利检索 ap:("AbbVie Inc.") AND inv:"Mark A. Matulenko" 第 1 页

1.

发明申请
CARBIDOPA PRODRUGS 审中-公开

公开(公告)号：US20200262852A1

公开(公告)日：2020-08-20

申请号：US16866400

申请日：2020-05-04

申请人： AbbVie Inc.

发明人： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff Zhang

IPC分类号： C07F9/09 , A61K45/06 , A61K31/6615 , C07C47/277 , C07C309/24 , C07C281/02 , C07F9/06 , A61K31/661

摘要： The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

2.

发明申请
Anti-Viral Compounds 审中-公开

公开(公告)号：US20170157104A1

公开(公告)日：2017-06-08

申请号：US15431069

申请日：2017-02-13

申请人： AbbVie Inc.

发明人： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller

IPC分类号： A61K31/454 , A61K31/4184 , A61K31/4439 , A61K31/422 , A61K31/438 , A61K31/4178 , A61K31/695 , A61K31/496 , A61K31/506 , A61K31/4418 , A61K31/5377 , A61K31/4355 , A61K45/06 , A61K31/4545

CPC分类号： A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582

摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

3.

发明申请
Methods for Treating HCV 审中-公开

公开(公告)号：US20140080869A1

公开(公告)日：2014-03-20

申请号：US14029324

申请日：2013-09-17

申请人： AbbVie Inc.

发明人： Preethi KRISHNAN , Teresa (Iok-Chan) NG , Tami J. PILOT-MATIAS , Warren M. KATI , Clarence J. MARING , Neeta C. MISTRY , Thomas J. REISCH , Rolf WAGNER , Dachun LIU , John K. PRATT , Mark A. Matulenko , Ryan G. KEDDY

IPC分类号： A61K31/454 , A61K45/06

CPC分类号： A61K31/454 , A61K31/4184 , A61K45/06 , A61K2300/00

摘要： Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.

4.

发明公开
CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE 审中-公开

公开(公告)号：US20240024338A1

公开(公告)日：2024-01-25

申请号：US18334738

申请日：2023-06-14

申请人： AbbVie Inc.

发明人： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao. , Xiaochun Lou , Sean Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang

IPC分类号： A61K31/661 , A61K9/00 , A61K9/14 , A61K45/06 , A61K9/08 , C07F9/12

CPC分类号： A61K31/661 , A61K9/0019 , A61K9/14 , A61K45/06 , A61K9/08 , C07F9/12

摘要： The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

5.

发明授权
Anti-viral compounds 有权
标题翻译：抗病毒化合物

公开(公告)号：US09586978B2

公开(公告)日：2017-03-07

申请号：US14558318

申请日：2014-12-02

申请人： AbbVie Inc.

发明人： Mary E. Bellizzi , David A. Betebenner , Jean C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller

IPC分类号： A61K38/00 , C07K16/00 , C07F7/02 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113

CPC分类号： A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582

摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

摘要翻译： 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

6.

发明申请
6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE 有权
标题翻译： 6-异亮氨酸或6-芳基喹啉-2-羧酸酰胺及其使用方法

公开(公告)号：US20160355482A1

公开(公告)日：2016-12-08

申请号：US15239554

申请日：2016-08-17

申请人： AbbVie Inc.

发明人： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield

IPC分类号： C07D215/48 , C07D409/14 , C07D487/08 , C07D471/04 , C07D487/04 , C07D405/14 , C07D417/14 , C07D401/12 , C07D401/14

CPC分类号： C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08

摘要： Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

摘要翻译： 和其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如说明书中所定义，可用于治疗由电压门控钠通道（例如Nav1）预防或改善的病症或病症。 7和/或Nav1.8。公开了制备化合物的方法。还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。

7.

发明申请
ANTI-VIRAL COMPOUNDS 有权

公开(公告)号：US20140315792A1

公开(公告)日：2014-10-23

申请号：US14180886

申请日：2014-02-14

申请人： AbbVie, Inc.

发明人： Rolf Wagner , John K. Pratt , Dachun Liu , Michael D. Tufano , David A. DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Dooner , John T. Randolph , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , David A. Betebenner , Kathy Sarris , Kevin R. Woller , Seble H. Wagaw , Jean C. Califano , Wenke Li , Daniel D. Caspi , Mary E. Bellizzi , Yi Gao , Allan C. Krueger

IPC分类号： C07K5/06 , C07D417/14 , C07C33/26 , C07D403/14 , C07C205/19

CPC分类号： C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06

摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

8.

发明申请
METHODS OF TREATING PARKINSON'S DISEASE 有权

公开(公告)号：US20220153765A1

公开(公告)日：2022-05-19

申请号：US17378321

申请日：2021-07-16

申请人： AbbVie Inc.

发明人： Benoit Cardinal-David , Vincent S. Chan , Kassibla Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang

IPC分类号： C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06

摘要： The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

9.

发明申请
Carbidopa Prodrug 审中-公开

公开(公告)号：US20190375770A1

公开(公告)日：2019-12-12

申请号：US16210996

申请日：2018-12-05

申请人： AbbVie Inc.

发明人： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christiopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang

IPC分类号： C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06

摘要： The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.